Cold agglutinin disease and cryoglobulinemia

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cold agglutinin disease is a form of direct, extravascular, antiglobulin-positive hemolysis. In vivo, immunoglobulin (Ig) M fixes complement molecules to the red cell membrane. Successive passages through the mononuclear phagocyte system result in loss of red cell membrane. The resultant spherocytes lose resiliency and are ultimately lost from the circulation extravascularly. The high concentration of complement molecules on the red cell surfaces makes this syndrome resistant to the standard therapies for immune-mediated hemolysis. Rituximab has been reported to reduce the severity of hemolysis. Type II cryoglobulins are composed of a monoclonal IgM and a polyclonal IgG. These complexes have rheumatoid factor activity and can produce immune-complex vasculitis. The target organs are the skin, nerves, kidney, liver, and joints. More than 80% of patients have evidence of hepatitis C infection. Interferon and interferon plus ribavirin have been shown to produce serologic responses. When vasculitis is active, corticosteroids are often required to permit healing of ulcers in the skin or to treat the membranoproliferative glomerulonephritis that is seen, thereby preventing loss of renal function. Rituximab therapy has been found to be effective in mixed cryoglobulinemia, with decreases in cryoglobulin values and improvement in complement values.

Original languageEnglish (US)
Pages (from-to)290-293
Number of pages4
JournalClinical Lymphoma
Volume5
Issue number4
DOIs
StatePublished - Jan 1 2005

Fingerprint

Cryoglobulinemia
Autoimmune Hemolytic Anemia
Hemolysis
Cryoglobulins
Vasculitis
Interferons
Immunoglobulin M
Spherocytes
Cell Membrane
Skin Ulcer
Membranoproliferative Glomerulonephritis
Kidney
Mononuclear Phagocyte System
Rheumatoid Factor
Ribavirin
Hepatitis C
Antigen-Antibody Complex
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Immunoglobulin G

Keywords

  • Cryoglobulin
  • Hemolytic anemia
  • Hepatitis
  • Rituximab
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cold agglutinin disease and cryoglobulinemia. / Gertz, Morie.

In: Clinical Lymphoma, Vol. 5, No. 4, 01.01.2005, p. 290-293.

Research output: Contribution to journalArticle

@article{8bcb79de20354e52bdb58f4a1f34dc00,
title = "Cold agglutinin disease and cryoglobulinemia",
abstract = "Cold agglutinin disease is a form of direct, extravascular, antiglobulin-positive hemolysis. In vivo, immunoglobulin (Ig) M fixes complement molecules to the red cell membrane. Successive passages through the mononuclear phagocyte system result in loss of red cell membrane. The resultant spherocytes lose resiliency and are ultimately lost from the circulation extravascularly. The high concentration of complement molecules on the red cell surfaces makes this syndrome resistant to the standard therapies for immune-mediated hemolysis. Rituximab has been reported to reduce the severity of hemolysis. Type II cryoglobulins are composed of a monoclonal IgM and a polyclonal IgG. These complexes have rheumatoid factor activity and can produce immune-complex vasculitis. The target organs are the skin, nerves, kidney, liver, and joints. More than 80{\%} of patients have evidence of hepatitis C infection. Interferon and interferon plus ribavirin have been shown to produce serologic responses. When vasculitis is active, corticosteroids are often required to permit healing of ulcers in the skin or to treat the membranoproliferative glomerulonephritis that is seen, thereby preventing loss of renal function. Rituximab therapy has been found to be effective in mixed cryoglobulinemia, with decreases in cryoglobulin values and improvement in complement values.",
keywords = "Cryoglobulin, Hemolytic anemia, Hepatitis, Rituximab, Waldenstr{\"o}m's macroglobulinemia",
author = "Morie Gertz",
year = "2005",
month = "1",
day = "1",
doi = "10.3816/CLM.2005.n.019",
language = "English (US)",
volume = "5",
pages = "290--293",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Cold agglutinin disease and cryoglobulinemia

AU - Gertz, Morie

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Cold agglutinin disease is a form of direct, extravascular, antiglobulin-positive hemolysis. In vivo, immunoglobulin (Ig) M fixes complement molecules to the red cell membrane. Successive passages through the mononuclear phagocyte system result in loss of red cell membrane. The resultant spherocytes lose resiliency and are ultimately lost from the circulation extravascularly. The high concentration of complement molecules on the red cell surfaces makes this syndrome resistant to the standard therapies for immune-mediated hemolysis. Rituximab has been reported to reduce the severity of hemolysis. Type II cryoglobulins are composed of a monoclonal IgM and a polyclonal IgG. These complexes have rheumatoid factor activity and can produce immune-complex vasculitis. The target organs are the skin, nerves, kidney, liver, and joints. More than 80% of patients have evidence of hepatitis C infection. Interferon and interferon plus ribavirin have been shown to produce serologic responses. When vasculitis is active, corticosteroids are often required to permit healing of ulcers in the skin or to treat the membranoproliferative glomerulonephritis that is seen, thereby preventing loss of renal function. Rituximab therapy has been found to be effective in mixed cryoglobulinemia, with decreases in cryoglobulin values and improvement in complement values.

AB - Cold agglutinin disease is a form of direct, extravascular, antiglobulin-positive hemolysis. In vivo, immunoglobulin (Ig) M fixes complement molecules to the red cell membrane. Successive passages through the mononuclear phagocyte system result in loss of red cell membrane. The resultant spherocytes lose resiliency and are ultimately lost from the circulation extravascularly. The high concentration of complement molecules on the red cell surfaces makes this syndrome resistant to the standard therapies for immune-mediated hemolysis. Rituximab has been reported to reduce the severity of hemolysis. Type II cryoglobulins are composed of a monoclonal IgM and a polyclonal IgG. These complexes have rheumatoid factor activity and can produce immune-complex vasculitis. The target organs are the skin, nerves, kidney, liver, and joints. More than 80% of patients have evidence of hepatitis C infection. Interferon and interferon plus ribavirin have been shown to produce serologic responses. When vasculitis is active, corticosteroids are often required to permit healing of ulcers in the skin or to treat the membranoproliferative glomerulonephritis that is seen, thereby preventing loss of renal function. Rituximab therapy has been found to be effective in mixed cryoglobulinemia, with decreases in cryoglobulin values and improvement in complement values.

KW - Cryoglobulin

KW - Hemolytic anemia

KW - Hepatitis

KW - Rituximab

KW - Waldenström's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=18144404191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144404191&partnerID=8YFLogxK

U2 - 10.3816/CLM.2005.n.019

DO - 10.3816/CLM.2005.n.019

M3 - Article

C2 - 15794868

AN - SCOPUS:18144404191

VL - 5

SP - 290

EP - 293

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -